TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study)
Phase of Trial: Phase IV
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
- Indications Ankylosing spondylitis; Spondylarthritis
- Focus Therapeutic Use
- Acronyms TRACE
- 02 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2018 to 1 Sep 2018.
- 23 Sep 2018 Status changed from not yet recruiting to recruiting.
- 07 Mar 2018 New trial record